MedCity News

AUGUST 7, 2023

The regulatory decision comes as safety concerns emerge around the first therapy for the disease, an Apellis Pharmaceuticals product. Izervay, a drug developed by Astellas Pharma subsidiary Iveric Bio, is now the second approved therapy for the degenerative vision-loss disorder geographic atrophy.

Pharmaceutical products 244

Pharmaceutical products Safety FDA Pharma 244

European Pharmaceutical Review

APRIL 17, 2023

A report on automation in the biopharma industr y has shown that the market is projected to grow at a compound annual growth rate (CAGR) of 5.7 Factors impacting the automation in the biopharma industry market The report found that 75 percent of pharmaceutical organisations want to use automated solutions more frequently.

Biopharma 98

Biopharma Manufacturing Pharmaceutical products Marketing 98

pharmaphorum

SEPTEMBER 28, 2022

In recent years, the biopharma market has become progressively complex. As a result, payers are feeling increased pressure to make the right decisions based on the perceived value of each product. HTA agencies can assist biopharma companies at the early stages of development to ensure they are meeting the expectations of payers.

Biopharma 52

Biopharma Side effects Consulting Pharmaceutical products 52

Clarivate

MARCH 14, 2024

With the introduction of a new CMC Intelligence entitlement to address post-approval changes, Clarivate now covers a broader range of the lifecycle of pharmaceutical products. Future research could focus on developing PFAS-free packaging materials that meet regulatory standards without compromising safety.

Pharmaceutical 52

Pharmaceutical Manufacturing Food Healthcare Provider 52